logo-loader
Micro Focus International plc

Micro Focus has completed its recovery, says Barclays as it downgrades software giant

The software group plunged this time last year, but the shares have rallied in recent months, to the point where Barclays thinks they are now fairly valued

micro focus
There isn’t enough upside to justify an ‘overweight’ rating, according to Barclays

Barclays has been impressed by Micro Focus PLC’s (LON:MCRO) bounce back since its profit warning this time last year, but warned investors that the stock is now fairly valued.

Last March, the software group shocked the market when it parted ways with chief executive Chris Hsu after slashing its revenue guidance.

Shares plunged on the news and fell below 1,000p. But they have since recovered and are now trading at similar levels to before the profit warning.

READ: Micro Focus shares crash as it cuts revenue guidance, CEO resigns

“Ultimately, trading never deteriorated to the extent feared,” said Barclays in a note to clients.

Micro Focus has made very significant progress since the warning and the business has stabilised. We are encouraged by the progress and anticipate ongoing positive momentum in earnings.

“However, while the stock still looks cheap on headline P/E, it has, in our view, reached fair value on an enterprise basis.”

The analysts concluded: “Despite increasing our price target to 2,000p due to the rerating of the market, we cannot find sufficient upside to maintain an ‘overweight’ rating. We therefore downgrade to ‘equal weight’.”

Micro Focus shares were down 0.3% to 1,939p in late-morning trading on Friday.

Quick facts: Micro Focus International plc

Price: £11.62

Market: LSE
Market Cap: £38.97 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Lexagene Develops technology to test for deadly mosquito...

Lexagene (CVE: LXG-OTCQB-LXXGF) Founder and CEO Dr jack Regan joined Steve Darling from Proactive Vancouver on Skype with news the company has used their proprietary technology to develop a detection system for the Eastern Equine Encephalitis or EEE. Regan says that not only can they use the...

41 minutes ago

RNS

Transaction in Own Shares

11 hours, 32 minutes ago

Transaction in Own Shares

1 day, 11 hours ago

Transaction in Own Shares

4 days, 11 hours ago

Transaction in Own Shares

5 days, 11 hours ago

Transaction in Own Shares

6 days, 11 hours ago

Transaction in Own Shares

1 week, 1 day ago

2 min read